Effect of single intravenous administration of batroxobin on erythrocyte aggregability in patients with acute-stage cerebral infarction

N. Tanahashi, Y. Fukuuchi, M. Tomita, M. Kobari, H. Takeda, M. Yokoyama, Daisuke Ito

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We examined the effect of defibrinogenation with batroxobin on the erythrocyte aggregability (RBC-A) in 16 patients with cerebral infarction during the acute phase (less than 72 hours after onset). Eight patients received a single intravenous administration of 10 units of batroxobin (BU), while the other 8 patients received 5 BU. The RBC-A was examined using the whole-blood erythrocyte aggregometer developed by us (Am. J. Physiol. 251, H1205–H1210, 1986) with concomitant measurement of the hematocrit, albumin:globulin ratio and concentration of fibrinogen. The RBC-A values before, and at 1,2, and 7 days after 10 BU administration were 0.154±0.017/s, 0.117±0.029/s (76% of the value before the administration, P<0.01), 0.105±0.029/s (68%, P<0.01), and 0.124±0.015/s (81%, P<0.01), respectively. The fibrinogen concentrations before, and at 1, 2, and 7 days after the batroxobin were 364±81 mg/dl, 150±35 mg/dl (41%, P<0.01), 129±35 mg/dl (35%, P<0.01), and 211±42 mg/dl (58%, P<0.01), respectively. On the other hand, the RBC-A values before, and at 1, 2, and 7 days after 5 BU administration were 0.143±0.021/s, 0.131±0.036/s, 0.130±0.028/s, and 0.141±0.029/s, respectively. The fibrinogen concentrations before, and at 1, 2, and 7 days after the batroxobin were 318±57 mg/dl, 255±60 mg/dl (80%, P<0.01), 259±68 mg/dl (81%, P<0.01), and 319±87 mg/dl, respectively. We conclude that a single intravenous administration of batroxobin at 10 BU reduced the RBC-A in patients with cerebral infarction during the acute phase in accordance with a decrease in the fibrinogen level. The effect appeared to last for more than 7 days.

Original languageEnglish
Pages (from-to)89-96
Number of pages8
JournalClinical Hemorheology and Microcirculation
Volume15
Issue number1
DOIs
Publication statusPublished - 1995 Jan 1

Fingerprint

Batroxobin
Cerebral Infarction
Intravenous Administration
Erythrocytes
Fibrinogen
Globulins
Hematocrit
Albumins

Keywords

  • Batroxobin
  • Cerebral infarction
  • Defibrinogenation
  • Erythrocyte aggregation
  • Hemorheology

ASJC Scopus subject areas

  • Physiology
  • Hematology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Effect of single intravenous administration of batroxobin on erythrocyte aggregability in patients with acute-stage cerebral infarction. / Tanahashi, N.; Fukuuchi, Y.; Tomita, M.; Kobari, M.; Takeda, H.; Yokoyama, M.; Ito, Daisuke.

In: Clinical Hemorheology and Microcirculation, Vol. 15, No. 1, 01.01.1995, p. 89-96.

Research output: Contribution to journalArticle

@article{baf9ff3f0f1840b4825e06e138d68022,
title = "Effect of single intravenous administration of batroxobin on erythrocyte aggregability in patients with acute-stage cerebral infarction",
abstract = "We examined the effect of defibrinogenation with batroxobin on the erythrocyte aggregability (RBC-A) in 16 patients with cerebral infarction during the acute phase (less than 72 hours after onset). Eight patients received a single intravenous administration of 10 units of batroxobin (BU), while the other 8 patients received 5 BU. The RBC-A was examined using the whole-blood erythrocyte aggregometer developed by us (Am. J. Physiol. 251, H1205–H1210, 1986) with concomitant measurement of the hematocrit, albumin:globulin ratio and concentration of fibrinogen. The RBC-A values before, and at 1,2, and 7 days after 10 BU administration were 0.154±0.017/s, 0.117±0.029/s (76{\%} of the value before the administration, P<0.01), 0.105±0.029/s (68{\%}, P<0.01), and 0.124±0.015/s (81{\%}, P<0.01), respectively. The fibrinogen concentrations before, and at 1, 2, and 7 days after the batroxobin were 364±81 mg/dl, 150±35 mg/dl (41{\%}, P<0.01), 129±35 mg/dl (35{\%}, P<0.01), and 211±42 mg/dl (58{\%}, P<0.01), respectively. On the other hand, the RBC-A values before, and at 1, 2, and 7 days after 5 BU administration were 0.143±0.021/s, 0.131±0.036/s, 0.130±0.028/s, and 0.141±0.029/s, respectively. The fibrinogen concentrations before, and at 1, 2, and 7 days after the batroxobin were 318±57 mg/dl, 255±60 mg/dl (80{\%}, P<0.01), 259±68 mg/dl (81{\%}, P<0.01), and 319±87 mg/dl, respectively. We conclude that a single intravenous administration of batroxobin at 10 BU reduced the RBC-A in patients with cerebral infarction during the acute phase in accordance with a decrease in the fibrinogen level. The effect appeared to last for more than 7 days.",
keywords = "Batroxobin, Cerebral infarction, Defibrinogenation, Erythrocyte aggregation, Hemorheology",
author = "N. Tanahashi and Y. Fukuuchi and M. Tomita and M. Kobari and H. Takeda and M. Yokoyama and Daisuke Ito",
year = "1995",
month = "1",
day = "1",
doi = "10.3233/CH-1995-15111",
language = "English",
volume = "15",
pages = "89--96",
journal = "Clinical Hemorheology and Microcirculation",
issn = "1386-0291",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Effect of single intravenous administration of batroxobin on erythrocyte aggregability in patients with acute-stage cerebral infarction

AU - Tanahashi, N.

AU - Fukuuchi, Y.

AU - Tomita, M.

AU - Kobari, M.

AU - Takeda, H.

AU - Yokoyama, M.

AU - Ito, Daisuke

PY - 1995/1/1

Y1 - 1995/1/1

N2 - We examined the effect of defibrinogenation with batroxobin on the erythrocyte aggregability (RBC-A) in 16 patients with cerebral infarction during the acute phase (less than 72 hours after onset). Eight patients received a single intravenous administration of 10 units of batroxobin (BU), while the other 8 patients received 5 BU. The RBC-A was examined using the whole-blood erythrocyte aggregometer developed by us (Am. J. Physiol. 251, H1205–H1210, 1986) with concomitant measurement of the hematocrit, albumin:globulin ratio and concentration of fibrinogen. The RBC-A values before, and at 1,2, and 7 days after 10 BU administration were 0.154±0.017/s, 0.117±0.029/s (76% of the value before the administration, P<0.01), 0.105±0.029/s (68%, P<0.01), and 0.124±0.015/s (81%, P<0.01), respectively. The fibrinogen concentrations before, and at 1, 2, and 7 days after the batroxobin were 364±81 mg/dl, 150±35 mg/dl (41%, P<0.01), 129±35 mg/dl (35%, P<0.01), and 211±42 mg/dl (58%, P<0.01), respectively. On the other hand, the RBC-A values before, and at 1, 2, and 7 days after 5 BU administration were 0.143±0.021/s, 0.131±0.036/s, 0.130±0.028/s, and 0.141±0.029/s, respectively. The fibrinogen concentrations before, and at 1, 2, and 7 days after the batroxobin were 318±57 mg/dl, 255±60 mg/dl (80%, P<0.01), 259±68 mg/dl (81%, P<0.01), and 319±87 mg/dl, respectively. We conclude that a single intravenous administration of batroxobin at 10 BU reduced the RBC-A in patients with cerebral infarction during the acute phase in accordance with a decrease in the fibrinogen level. The effect appeared to last for more than 7 days.

AB - We examined the effect of defibrinogenation with batroxobin on the erythrocyte aggregability (RBC-A) in 16 patients with cerebral infarction during the acute phase (less than 72 hours after onset). Eight patients received a single intravenous administration of 10 units of batroxobin (BU), while the other 8 patients received 5 BU. The RBC-A was examined using the whole-blood erythrocyte aggregometer developed by us (Am. J. Physiol. 251, H1205–H1210, 1986) with concomitant measurement of the hematocrit, albumin:globulin ratio and concentration of fibrinogen. The RBC-A values before, and at 1,2, and 7 days after 10 BU administration were 0.154±0.017/s, 0.117±0.029/s (76% of the value before the administration, P<0.01), 0.105±0.029/s (68%, P<0.01), and 0.124±0.015/s (81%, P<0.01), respectively. The fibrinogen concentrations before, and at 1, 2, and 7 days after the batroxobin were 364±81 mg/dl, 150±35 mg/dl (41%, P<0.01), 129±35 mg/dl (35%, P<0.01), and 211±42 mg/dl (58%, P<0.01), respectively. On the other hand, the RBC-A values before, and at 1, 2, and 7 days after 5 BU administration were 0.143±0.021/s, 0.131±0.036/s, 0.130±0.028/s, and 0.141±0.029/s, respectively. The fibrinogen concentrations before, and at 1, 2, and 7 days after the batroxobin were 318±57 mg/dl, 255±60 mg/dl (80%, P<0.01), 259±68 mg/dl (81%, P<0.01), and 319±87 mg/dl, respectively. We conclude that a single intravenous administration of batroxobin at 10 BU reduced the RBC-A in patients with cerebral infarction during the acute phase in accordance with a decrease in the fibrinogen level. The effect appeared to last for more than 7 days.

KW - Batroxobin

KW - Cerebral infarction

KW - Defibrinogenation

KW - Erythrocyte aggregation

KW - Hemorheology

UR - http://www.scopus.com/inward/record.url?scp=0028887579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028887579&partnerID=8YFLogxK

U2 - 10.3233/CH-1995-15111

DO - 10.3233/CH-1995-15111

M3 - Article

AN - SCOPUS:0028887579

VL - 15

SP - 89

EP - 96

JO - Clinical Hemorheology and Microcirculation

JF - Clinical Hemorheology and Microcirculation

SN - 1386-0291

IS - 1

ER -